Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a tumultuous bidding war with Novo Nordisk A/S ...

Pfizer has submitted a sweetened bid for Metsera, an obesity drug developer, as its fight against rival Novo Nordisk ...

Obesity drug developer Metsera said on Friday that it had accepted Pfizer's $10 billion acquisition offer, in what could ...

Pfizer Inc. has agreed to buy Metsera Inc. for $10 billion, surpassing Novo Nordisk in a competitive bidding war. Details of ...

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after ...

Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, ...

Pfizer and Novo Nordisk have locked horns in a bidding war over Metsera – a US-based biotech in the process of developing new ...

Metsera, an obesity drug developer, has accepted a $10 billion acquisition offer from pharmaceutical giant Pfizer, potentially concluding a bidding war with Novo Nordisk.

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.